MDB's Business Model and Strategy - MDB aims to transform disruptive technology "Big Ideas" into valuable public companies[9] - The company's goal is to enable investors to create a portfolio of 10–12 MDB curated public venture companies over time[11] - MDB's platform helps stand up and launch disruptive tech new category leaders[14] - MDB is curating deals with companies that have the potential to become market leaders in the technology category at valuations that make them financeable in the public markets[23] Market Opportunity and IPO Trends - There is pent-up demand for IPOs among early-stage micro-cap companies, but fewer completed listings[21] - A valuation mismatch between issuers and VCs is restraining micro-cap companies from launching IPOs[22] - MDB is focused on curating deals with the right companies at the right valuations to take them public[23] Financial Performance and Investments - MDB closed a public offering for HeartBeam, Inc (NASDAQ: BEAT) with gross proceeds of approximately $11.5 million[26] - The company completed LOIs for 3 new "Big Idea" companies to launch in 2025[26] - As of March 31, 2025, MDB's total cash and securities were $67.1 million, compared to $93.2 million on December 31, 2024[28] - Investments in eXoZymes were valued at $40.9 million for GAAP purposes as of March 31, 2025[30] Investor Community and Initiatives - MDB increased its MDBH shareholder base by 4.5%[27] - The company onboarded 111 new MDB Direct accounts, a 26% increase in Q1 2025[27]

Financial Data and Key Metrics Changes - The company reported a modest increase in its shareholder base, onboarding several new accounts interested in the HeartBeam offering [30] - Net current assets decreased by approximately $2.3 million, with less than $2 million in cash utilized during the quarter [36][37] - The enterprise value calculation indicates that the company was trading at a significant discount to its enterprise value at year-end, which has slightly decreased due to volatility in HeartBeam and Exozymes [34][35] Business Line Data and Key Metrics Changes - The company is pivoting towards companies that are closer to product revenue and value creation, indicating a shift in focus from traditional deep tech ideas [19][50] - The company has three new Letters of Intent (LOIs) with a biotech firm, a profitable beverage company, and a healthcare software company, all of which are expected to perform well in the public markets [20][21][23] Market Data and Key Metrics Changes - The venture market is experiencing a significant backlog of companies that could potentially go public, with many venture firms seeking to exit investments due to a lack of new fund formations [12][15] - The current environment is seen as favorable for small IPOs, with a growing number of companies that could be well-valued in public markets [18][51] Company Strategy and Development Direction - The company aims to curate public venture capital as a preferred alternative to traditional venture capital, focusing on transforming big ideas into valuable public companies [5][6] - The management is excited about the potential for IPOs, believing that the current market dynamics will allow for better valuations and opportunities for public investors [15][16] - The company is expanding its investor community, focusing on capital allocators rather than just deal buyers, to enhance its deal flow [50][45] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging operating environment but remains optimistic about the potential for future growth and the ability to bring new companies public [24][51] - The management believes that the current market conditions will lead to a resurgence in small IPOs, reversing long-term downtrends [18][51] - The company is committed to finding extraordinary businesses at the right valuations, which will represent great return opportunities for investors [20][52] Other Important Information - The company has restructured its executive compensation plan to align better with shareholder interests, converting a significant amount of stock into options [32][33] - PatentVest is seen as a critical component of the company's strategy, providing essential business development and IP strategy support to portfolio companies [69][70] Q&A Session Summary Question: Can you just talk about the one company that you have that you're financing, the 20,000,000 for the potential cure for diabetes? - The company being financed is PaulX Bio [54] Question: How does management interpret the persistent discount of the MDBH stock price relative to the IPO price? - Management attributes the discount to supply and demand dynamics, noting that market perceptions can change over time [56][59] Question: What is the future dividend policy of the company? - The dividend policy will depend on the impact of share distribution on the companies involved and the company's cash flows [60][62] Question: How does MDB make money when taking a venture public? - MDB earns equity through pre-IPO financing and charges cash fees, often receiving a blend of cash and equity [65][66] Question: Can you share how much of MDB's value is due to its share of ownership of the companies you've taken public? - The value is significantly tied to the performance of companies like Exozymes and HeartBeam, with potential for substantial impact on MDB's stock price [77][79] Question: Do you ever consider acquisition of companies instead of IPOs? - Currently, the focus is on public venture, but acquisitions could be considered if they align with the company's strategy [81] Question: How many firms do you see out there that are doing what MDB Capital is doing currently? - Management believes there are very few firms that effectively compete with MDB's unique approach to public venture capital [82][84]

Financial Data and Key Metrics Changes - The company reported a modest increase in its shareholder base, onboarding several new accounts interested in the HeartBeam offering [29] - Net current assets decreased by approximately $2.3 million, with less than $2 million in cash utilized during the quarter [35] Business Line Data and Key Metrics Changes - The company is pivoting towards companies that are closer to product revenue and value creation, indicating a shift in focus from deep tech ideas to more profitable ventures [19][48] - The company has three letters of intent (LOIs) with new companies, including a biotech firm with a pre-money valuation of $20 million, a profitable beverage company, and a healthcare software company [20][22][23] Market Data and Key Metrics Changes - The current venture market is characterized by a significant number of companies that have received funding but have not gone public, creating opportunities for the company to take these firms public [11][12] - The company noted a backlog of IPO opportunities due to changing market dynamics, with investors preferring companies that are capital light and closer to profitability [15][17] Company Strategy and Development Direction - The company aims to scale its operations by bringing three to four new investment opportunities to the public market each year, focusing on companies that can resonate in the changing marketplace [43][44] - The management emphasized the importance of valuation and the need to find extraordinary businesses at the right values to provide great return opportunities for investors [20][50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the small IPO market, suggesting it will be robust and may reverse long-standing downtrends [17] - The management acknowledged the current challenging environment for small companies but remains confident in the company's ability to curate and take public viable businesses [24][49] Other Important Information - The company has restructured its executive compensation plan to align better with shareholder interests, converting a significant amount of stock compensation to options [31][32] - PatentVest is seen as a critical component for value creation, assisting in business development and strategy for the companies it works with [66][70] Q&A Session Summary Question: Can you talk about the company financing the $20 million for the potential cure for diabetes? - The company financing this is PaulX Bio [52] Question: How does management interpret the persistent discount of the MDBH stock price relative to the IPO price? - Management believes it is primarily a supply and demand issue, noting that market perceptions can change over time [54][56] Question: What is the future dividend policy? - The dividend policy will depend on the impact of share distribution on the companies involved and the company's cash flows [58][60] Question: How does the company make money when taking a venture public? - The company earns equity through pre-IPO financing and charges cash fees, often receiving a blend of cash and equity [62][63] Question: How much of MDB's value is due to its share of ownership of the companies taken public? - The company believes that if it had gone public at a better time, its valuation would be significantly higher [74][76] Question: Does the company consider acquisitions instead of IPOs? - Currently, the focus is on public ventures, but the company would consider acquisitions if they are accretive to its public venture strategy [79] Question: How many firms are doing what MDB Capital is doing currently? - Management believes there are very few firms left that can effectively take small companies public, highlighting the company's unique position [81][82]

NASDAQ: MDBH We make investments that can change lives Fourth Quarter and Full Year 2024 Results March 31, 2025 FORWARD-LOOKING STATEMENTS & DISCLOSURES This presentation contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "go ...